Johnson Center | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

108,045 results for “Johnson Center”

Trials

View all 90777 →

Stevens-Johnson Syndrome Antimicrobial

1 participants · First posted Feb 13, 2009

A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products

1,674 participants · First posted May 27, 2022

Evaluation of a Johnson & Johnson Vision Care Investigational Contact Lens Compared to a Marketed Monthly Replacement Contact Lens

224 participants · First posted Aug 5, 2015

Drugs

View all 2011 →

OCTR lymphocytes(Johnson & Johnson)

H3 receptor antagonists(Johnson & Johnson)

RWJ 445167 prodrugs (Johnson & Johnson)

Organizations

View all 1687 →

RALPH H. JOHNSON VA MEDICAL CENTER

United States

Johnson & Johnson

United States

Johnson & Johnson Ltd.

United Kingdom

News

View all 13570 →

Coya Therapeutics Advances Treg Exosome Platform for Neurodegenerative Disease Treatment

Subcutaneous Amivantamab Plus Lazertinib Shows 70% 3-Year Survival in EGFR-Mutated NSCLC

Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio

Page 1 of 10805